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BACKGROUND: Dicer, a ribonuclease, is the key enzyme required for the biogenesis of microRNAs and small interfering RNAs and is
essential for both mammalian development and cell differentiation. Recent evidence indicates that Dicer may also be involved in
tumourigenesis. However, no studies have examined the clinical significance of Dicer at both the RNA and the protein levels in breast
cancer.
METHODS: In this study, the biological and prognostic value of Dicer expression was assessed in breast cancer cell lines, breast cancer
progression cellular models, and in two well-characterised sets of breast carcinoma samples obtained from patients with long-term
follow-up using tissue microarrays and quantitative reverse transcription–PCR.
RESULTS: We have found that Dicer protein expression is significantly associated with hormone receptor status and cancer subtype in
breast tumours (ER P¼0.008; PR P¼0.019; cancer subtype P¼0.023, luminal A P¼0.0174). Dicer mRNA expression appeared to
have an independent prognostic impact in metastatic disease (hazard ratio¼3.36, P¼0.0032). In the breast cancer cell lines, lower
Dicer expression was found in cells harbouring a mesenchymal phenotype and in metastatic bone derivatives of a breast cancer cell
line. These findings suggest that the downregulation of Dicer expression may be related to the metastatic spread of tumours.
CONCLUSION: Assessment of Dicer expression may facilitate prediction of distant metastases for patients suffering from breast cancer.
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Breast cancer is the leading cancer diagnosis among women in the
western world. With ever-improving chemotherapeutic, radiation,
hormonal treatments, as well as HER2 and EGFR antagonists, an
improvement in overall survival has been observed. However, the
treatment of breast cancer is currently far from being optimal with
patients suffering from recurrent breast carcinoma usually dying
of the disease. Metastasis represents one of the final stages of the
potentially lethal evolution of breast cancer. The natural progres-
sion of breast cancer differs greatly between patients, and
metastatic progression in breast cancer is a complex and largely
unknown process. The different biological behaviours observed
among the distinct breast cancer subtypes may suggest different
mechanisms of invasion and metastasis for breast tumours.
Current therapy decision making is increasingly governed by the
molecular classification of breast cancer (luminal A, luminal B,
basal like, HER2þ, hormone receptor status). Cancer subtypes
have characteristic sites to which they metastasise (Luck et al,
2008). A very common metastatic site for human breast cancer is
the bone. Genes involved in metastasis but not in primary
tumourigenicity have been identified, particularly in bone
metastases (Mundy, 2002). Identification of biological factors in
relation to metastatic evolution and patterns is important for the
optimal management of patients. We hypothesised that the
expression of Dicer could be one such marker of prognosis in
breast cancer.
The Dicer gene encodes a protein that functions as an RNase
endonuclease type III and is required for the RNA interference
and microRNA (miRNA) pathways. It produces miRNAs and small
interfering RNAs (siRNAs) from pre-miRNAs and dsRNA,
respectively. Dicer null mice are embryonically lethal with the
depletion of stem cells (Bernstein et al, 2003). Furthermore,
embryonic stem cells that lack Dicer are viable but incapable of
differentiation and show severe proliferation defects (Murchison
et al, 2005). Dicer has been shown to be essential in stem cell
maintenance by its involvement in auto-renewal and proliferation
(Jin and Xie, 2007).
Owing to its central role in the post-transcriptional regulation of
miRNA, Dicer is increasingly evoked in cancer-related studies.
miRNAs have been shown to be differentially expressed between
normal and malignant tissues (Volinia et al, 2006; Zhang et al., Received 16 April 2009; revised 21 June 2009; accepted 30 June 2009
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s2006). Clearly, distinct miRNA expression signatures are found in
different types of cancer (Calin et al, 2005; Iorio et al, 2005; Lu
et al, 2005; Blenkiron et al, 2007). As genomic changes and
transcriptional regulation of miRNA expression do not explain the
differences in miRNA profiles between normal and malignant
tissues, the deregulation of miRNA biogenesis was investigated in
some cancers (Zhang et al, 2006; Blenkiron et al, 2007). Therefore,
we asked whether the expression levels of Dicer could vary during
breast cancer progression both at the transcriptional and post-
transcriptional levels, as has been shown in ovarian, lung, and
prostate cancers (Chiosea et al, 2006, 2007; Flavin et al, 2008;
Merritt et al, 2008). We aim at answering this question using real-
time reverse transcription (RT)–PCR, tissue microarray (TMA),
and western blotting. In this study, we report an alteration in Dicer
expression that could be an independent prognostic factor for
metastatic evolution of breast tumours.
MATERIALS AND METHODS
Tumour samples
Frozen tissue samples were used for mRNA analyses, and paraffin-
embedded tissue blocks were used for immunohistochemical
analyses.
mRNA study Tissue specimens were obtained from Eric Tabone
(Biological Resources Department, Centre Le ´on Be ´rard, Lyon,
France, French agreement no. DC-2008–99) and were collected
before the initiation of any therapy from 104 patients suffering
from breast cancer diagnosed between 1992 and 1999, who
underwent surgery at the Centre Le ´on Be ´rard. Normal breast
tissue samples were also obtained from four individuals (healthy
individuals undergoing reduction surgery).
Immunohistochemical analysis Formalin-fixed paraffin-embed-
ded breast tumour samples obtained from 86 Centre Le ´on Be ´rard
(French agreement no. DC-2008–99) patients diagnosed in 1998
with invasive breast cancer were used. Normal breast tissue
samples were also obtained from eight individuals (four healthy
individuals undergoing reduction surgery and four breast cancer
patients with normal surrounding tissues). None of the partici-
pants evaluated in the mRNA study were present in the
immunohistochemical analyses. All human tissue samples were
collected after obtaining approval from the Comite ´ de Protection
des Personnes Lyon Est and by the institutional review board and
ethics committee of Centre Le ´on Be ´rard, with fully informed
patient consent.
Cellular models and cell lines
Human mammary epithelial cells (HMECs)-hTERT, HMECs-
hTERTþ LT, and HMLER (cells expressing hTERT, LT, and
H-rasV12) were first derived and kindly provided by RA Weinberg
and M Brooks (Whitehead Institute for Biomedical Research,
Ludwig Center for Molecular Oncology, MIT Department of
Biology, Cambridge, MA, USA). The BO2 bone derivative MDA-
MB-231 clone was kindly provided by P Clezardin (Research Unit
U664, Laennec School of Medicine, INSERM, Lyon, France), and
the single cell-derived progeny 2 (SCP2) bone derivative MDA-
MB-231 clone was kindly provided by Yibin Kang (Department
of Molecular Biology, Princeton University, Princeton, NJ, USA)
and Joan Massague (Cancer Biology and Genetics Program, and
Howard Hughes Medical Institute, Memorial Sloan-Kettering
Cancer Centre, NY, USA). The 67NR, 168 FARN, 4TO7, 66c14,
and 4T1 cell lines were first derived and kindly provided by
F Miller (Karmanos Cancer Centre, Detroit, MI, USA) (Miller et al,
1983). The human mammary HMECs-hTERT, HMECs-hTERTþ
LT, and HMLER cell lines, the SCP2 and BO2 bone derivatives, and
the mouse mammary tumour cell lines (67NR, 168 FARN, 4TO7,
66c14, and 4T1) were maintained as described (Aslakson
and Miller, 1992; Elenbaas et al, 2001; Minn et al, 2005; Garcia
et al, 2008). A total of 21 breast cancer cell lines were obtained
from the American Type Culture (http://www.ATCC.org) (CGC
Standard Sonl, Mobheim, France) (see Supplementary Materials
and Methods).
RNA extraction and real-time PCR
Total RNA extraction was performed with a phenol–chloroform
method, using TriReagent (Sigma-Aldrich, Saint Louis, MO, USA)
for cell lysis and PhaseLockGel tubes (Eppendorf, Hamburg,
Germany) for phase separation. After DNAse treatment, the DNA
contamination of each sample was checked by electrophoresis on
agarose gel. The synthesis of cDNA was performed using the First-
Strand cDNA Synthesis Kit (GE Healthcare, Chalfont St Giles, UK).
Transcription of the Dicer gene produces 14 different mRNAs, 11
alternatively spliced variants and 3 full-length forms (which
vary in their 30-untranslated region (30UTR)). We chose primer
sets to amplify the three a, b, and c full-length isoforms (http://
www.ncbi.nlm.nih.gov/ieb/research/acembly/). Primer sequences
and real-time PCR experimental procedures using the LightCycler
system (Roche Applied Science, Basel, Switzerland) are described
in Supplementary Materials and Methods.
For miRNA analysis, real-time PCR was carried out as
mentioned above, using TaqMan miRNA assays according to the
manufacturer’s instructions (Applied Biosystems, Foster city, CA,
USA) on an ABI Prism 7000. All miRNA data are expressed relative
to RNU44, a small nucleolar (sn) RNA TaqMan PCR performed
on the same sample. Expression variations were calculated using
the DDCt method. The Taqman miRNA reverse transcription kit
(hsa-miR-21: 4373090, has-miR-182: 4373271, has-miR-221:
4373077, sno202: 4380917, RNU44: 4373384) was used to amplify
the different miRNAs.
Immunohistochemistry
Formalin-fixed paraffin-embedded breast tumour samples were
inserted in triplicate using a 600-mm needle (Alphelys, Plaisir,
France) in three TMA blocks. All normal tissue samples were
analysed on full tissue sections. These blocks were subsequently
cut into 4mm-thick slices. After deparaffinisation and rehydrata-
tion, endogenous peroxidases were blocked by incubating the
slides in 5% hydrogen peroxide in sterile water. For heat-induced
antigen retrieval, tissue sections were boiled for 40min in 10mM
citrate buffer (pH 6) in a water bath. Non-specific binding was
blocked with a protein-blocking reagent (Immunotech, Marseille,
France) for 5min. Slides were then incubated overnight at 41C with
a mouse monoclonal anti-Dicer antibody (clone 13D6, Abcam,
Cambridge, UK) diluted at 1:150 using an antibody diluent
solution (Chem Mate, Dako, Trappes, France). After rinsing in
phosphate-buffered saline, the slides were incubated with a bio-
tinylated secondary antibody bound to a streptavidin-peroxidase
conjugate (Vectastain Elite ABC reagent, Vector, Abcys, Paris,
France). The bound antibody was shown by adding the substrate,
3,30-diamino benzidine (DAB substrate kit for peroxidase, Vector).
Sections were counterstained with haematoxylin. After dehydra-
tion and mounting, they were analysed independently by both a
pathologist and a technician. Both the intensity of cytoplasmic
staining (3 grades) and the percentage of positive tumour cells
were assessed. The intensity of staining was graded on a scale from
0 to 2: ‘0’ reflected a lack of immunoreactivity, ‘1’ reflected weak
immunoreactivity, and ‘2’ reflected strong immunoreactivity.
Cases of discordance were reviewed by both the investigators to
reach a consensus. The investigators were unaware of the RT–PCR
results while scoring staining.
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The sequences (designed by Eurogentech, Liege, Belgium) of the
siRNAs used in this study are as follows: si1Dcr 50-AGAGGUAC
UUAGGAAAUUU-30 (recognising Dicer variants a, b, and c) and
the corresponding siCt1 50-UUACCUCCUUAGAUACAAU-30;
si2Dcr 50-GGAGCUUGAUUUGCAUGAU-30 (recognising Dicer
variants a, b, and c), and the corresponding siCt2 50-CCAAACA
CGGCUUUCAAAU-30. Transfection of HeLa cells was performed
using jetSI-endo (Polyplus Transfection, Illkirch France), as
described by the manufacturer. Cells were plated at 2.5 10
5 and
transfected with 50nM of Dicer targeting siRNA or the correspond-
ing non-targeting siRNA twice at 24-h intervals. The cells were
harvested 48h after the second transfection, and gene silencing
was assessed using quantitative RT–PCR and western blot.
Immunoblot detection of Dicer
Cell pellets were lysed with TEB150 buffer (50mM HEPES; 150mM
NaCl; 2mM MgCl2;5 m M EGTA; 1mM DTT; 0.5% Triton X-100;
10% glycerol; 1mM Na3VO4;1 0 ml PIC-1 P2850, , and 10ml PIC-2
P5726, obtained from Sigma-Aldrich) for 30min on ice. Western
blot analyses were carried out as described previously (Wang et al,
2003) using a nitrocellulose membrane (BioRad, Marnes-la-
Coquette, France). Membranes were incubated overnight with a
1:1000 dilution of human anti-Dicer antibody (clone 13D6,
Abcam), or with a 1:750 dilution of mouse anti-Dicer antibody
(Ab 13502, Abcam) overnight, followed by an incubation with
1:3000 anti-mouse IgG (Dako P0260) for 1h at room temperature.
Dicer expression was detected using the ECL western blotting
detection and analysis system (GE Healthcare) according to the
manufacturer’s protocol. Relative protein expression was esti-
mated using Quantity One software (BioRad). The monoclonal
antibody used in this study for human Dicer recognises an epitope
present on full-length protein (218.7kDa) encoded by the three
full-length transcripts a, b, and c and present on alternative
proteins encoding by the d and e alternative transcripts (113.2 and
93kDa, respectively) (Figure 1). To compare Dicer mRNA and
protein levels, we quantified only the band corresponding to the
known molecular weight of the Dicer protein (218.7kDa).
Identification of epithelial and mesenchymal phenotypes
Epithelial and mesenchymal phenotypes were determined in the
21 breast cancer lines and in the human mammary tumour
progression cellular model by western blotting examining the
expression of E-cadherin (epithelial marker) and vimentin
(mesenchymal marker). Western blot analyses were carried out
as described previously (Wang et al, 2003). Mouse monoclonal
antibodies directed against E-cadherin (clone 36, Becton Dick-
inson, Glostrup, Denmark) and mouse monoclonal antibodies
directed against vimentin (clone V9, Dako) were used. Epithelial
and mesenchymal phenotypes were also determined by examining
the morphology of the cells using an inverted microscope
(Axiovert 25, Zeiss, Oberkochen, Germany).
Clinical database description
Explanatory variables were extracted from the Centre Le ´on
Be ´rard institutional breast cancer database, including those of
all patients who underwent initial surgery performed at the
institution since 1996. The database has been declared to the
French authorities (CNIL). Parameters of interest include the
clinical or surgical history of the patient, the histology of
the tumour, the treatments applied, and immunohisto-
chemical covariates (hormonal status, HER2). This breast cancer
database was updated regularly for the follow-up data until
the patient’s death was reported (letter to the referring physician
or registrar’s office). The information on the evolution of the
tumour in terms of local or distant recurrences is prospectively
registered.
Clinical parameters taken into account in this study were:
  clinical data (age, menopausal status, metastatic status at
diagnosis);
  histological data (histological type, pT (tumour size), metastatic
lymph nodes status, SBR grade);
  immunohistochemical data (hormonal status, HER2 if
available);
  cancer subtype (tumours were classified as luminal A, luminal
B, HER2þ, and basal like as described previously (Creighton
et al, 2009; Hugh et al, 2009)).
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Figure 1 Schematic representation of five Dicer mRNA variants and their corresponding proteins according to AceView (http://www.ncbi.nlm.nih.gov/
ieb/research/acembly/), transcription from the Dicer gene produces 14 mRNAs, 11 alternatively spliced variants and 3 full-length forms. The three full-length
mRNA variants a, b, and c, the corresponding full-length protein (218kDa) and the two alternatively spliced variants, d and e, and their corresponding
proteins (113 and 93kDa, respectively) are shown. Coloured areas represent the coding region and black bars represent 50UTR and 30UTR. Domain
structures are represented on proteins.
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Immunohistochemistry expression and RNA expression A com-
parison of the distribution of clinical parameters according to the
intensity of Dicer cytoplasmic staining (0/1 vs 2) was made using
Pearson’s w
2 test; Fisher’s exact test was used when the number of
patients was small. For each cell line and tumour sample, repeated
measurements of mRNA expression were obtained by replicating
the extraction and reverse transcription steps. The mean mRNA
expression and its 95% confidence interval were estimated using a
hierarchical model (Sullivan et al, 1999; Goldstein, 2003). In these
models, the mean mRNA expression of each cell line or tumour
was allowed to vary randomly and to deviate from the group
average according to within- and between-cell lines or tumour
variances. This method adjusted for the within-cell line or tumour
correlation from repeated observations, as well as estimated the
mean of mRNA expression of each tumour. The median mRNA
expression value was used to calculate a threshold separating low
(p8) and high (48) Dicer mRNA expressions among tumours.
Survival analysis The end point of interest was metastasis-free
survival defined as the time from the date of first diagnosis to the
date of distant metastasis diagnosis or to the date of last follow-up
for patients with no distant metastasis (censored observation).
Survival analysis was carried out among the subgroup of patients
with no metastasis at diagnosis. Survival estimates were calculated
using the Kaplan–Meier method (Kaplan and Meier, 1958). The
difference in survival estimates between the groups Dicer relative
cDNA quantity p8 and 48 was assessed using the log-rank test
(Peto et al, 1977), and hazard ratios (HRs) were calculated using a
Cox model.
Statistical analysis was carried out using SAS software version
9.1 (SAS OnlineDoc, Version 9, SAS Institute Inc., Cary, NC, USA)
and R (R Development Core Team (2007). R: a language and
environment for statistical computing R Foundation for Statistical
Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://
www.R-project.org) using the ‘nlme’ package (Pinheiro J, Bates D,
DebRoy S and Sarkar D and the R Core team (2007). nlme: Linear
and Nonlinear Mixed Effects Models. R package version 3.1–89).
RESULTS
Dicer expression in tumour and metastatic progression
cellular models and in breast cancer cell lines:
downregulation in the more advanced stages and in
mesenchymal phenotype breast cancer cell lines
We assessed whether Dicer expression could be regulated
transcriptionally and post-transcriptionally in the human cancer
progression model developed by Elenbaas et al (2001) consisting of
normal HMECs, HMECsþhTERT (telomerase catalytic subunit),
HMECsþLT (SV40 large-T antigen)þhTERT, and HMLER
(HMECsþLTþhTERTþH-rasV12). This model is believed to
resume breast cancer progression. Dicer expression was readily
detectable at both the mRNA and the protein levels in HMECs,
HMECsþhTERT, and HMECþLTþhTERT and was significantly
decreased in HMLER (Figures 2A and B). Loss of E-cadherin
(epithelial marker) and expression of vimentin (mesenchymal
marker) are hallmarks of epithelial–mesenchymal transition
(EMT). In this study, we examined the expression of E-cadherin
and vimentin by western blot in HMECs and the in the three
HMEC-derived cell lines. The morphological characteristics of
these cell lines were assessed using phase-contrast microscopy
(Figure 2C). Interestingly, we have shown that the decrease in
Dicer expression is associated with EMT. Dicer levels were lower in
the mesenchymal phenotype cell line, HMLER (Figure 2). HMLER
cells have been shown previously to be a mixed population of
mesenchymal and epithelial phenotype cells (Morel et al, 2008). In
this study, the majority of the population of HMLER cells analysed
were of the mesenchymal phenotype (Figures 2C and D). We
analysed Dicer protein expression in hTERTþLT-RAS with either
epithelial or mesenchymal phenotypes, and found that Dicer
levels in the mesenchymal phenotype cells were lower than those
observed in epithelial phenotype cells (data not shown). Given
that the actin cytoskeleton is deeply reorganised during EMT
(Zhang et al, 2009), we decided to compare the relative abundance
of Dicer protein to actin with the relative abundance of
Dicer protein to GAPDH by western blot. Using GAPDH as the
protein-loading control, we found the same decrease in Dicer
expression in HMLER cells compared with that in the other cell
lines (Supplementary Figure S1). The expression of Dicer protein
in epithelial phenotype cells relative to GAPDH was in the
order of five- to 10-fold more abundant than in mesenchymal
phenotype cells.
As the impact of a mesenchymal phenotype on the development
and spread of tumours is poorly understood, we asked whether the
downregulation of Dicer could be linked to tumour invasiveness.
As no human model for metastasis progression in mammary
tumour cells is available, we next analysed Dicer expression in a
mouse model of invasiveness (Aslakson and Miller, 1992). This
model consisted of five clonal tumour sub-lines derived from a
spontaneously arising mammary tumour in a BALB/c mouse. The
67NR sub-line was considered as non-metastatic, 168 FARN and
4TO7 sub-lines formed micrometastases, whereas the 66c14 and T1
derivatives readily metastasised with differential organ specificities
(Aslakson and Miller, 1992; Tester et al, 2001). They can be
classified as following from the less tumourigenic to the highest
67NRo168FARNo4TO7o66c14o4T1. The behaviour of these
tumour lines is believed to reflect the sequence of multi-step
metastasis progression. Therefore, we set out to compare the
expression profiles of Dicer mRNA and protein in these five sub-
lines to investigate whether Dicer could be differentially regulated
during metastasis progression. Dicer mRNA and protein levels
showed some discrepancies among the five sub-lines, and no
association was found between Dicer expression and capacities
of the cells to metastasise in vivo (Figures 3A and B). However,
we have found a correlation between Dicer protein levels and
epithelial–mesenchymal phenotype in these sub-lines. The mor-
phological characteristics of the five sub-lines were assessed using
phase-contrast microscopy (data not shown).
After lymph node invasion, breast cancer commonly causes
osteolytic metastases in the bone. We next addressed the issue of
whether Dicer could be downregulated in a bone metastasis model
of breast cancer cells. Mammary tumours do not spontaneously
metastasise to the bone in mice, as is the case in humans, which
hamper studies in animal models. We assessed Dicer expression in
two distinct bone metastasis subpopulations both derived from the
human breast cancer cell line MDA-MB-231. BO2 cells were
obtained after injection of MDA-MB-231 cells into the tail vein
(Bellahce `ne et al, 2007), and SCP2 cells were obtained after
an intra-cardiac injection of parental cells into immune-deficient
mice (Minn et al, 2005). Interestingly, we have found a
significantly decreased expression of Dicer both at the mRNA
and the protein levels in the BO2 and SCP2 cells in comparison
with the parental cells (Figures 3C and D).
Inactivation of Dicer is associated with impaired maturation of
miRNA (Cummins et al, 2006; Kumar et al, 2007; Wiesen and
Tomasi, 2009) We have studied the expression of three mature
miRNAs, namely miR-182, miR-221, and miR-21 that were
involved in the tumourigenesis in Dicer knocked-down human
tumour cells (Supplementary Figures S2A and B). The siRNA
directed against Dicer were efficient against the three isoforms
(a, b, and c) that coded for the full-length protein (Figure 1). In
Dicer knocked-down cells as compared with controlled siRNA-
transfected cells, we observed a global decrease in the three mature
miRNAs (Supplementary Figure S2B). However, despite a strong
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Figure 2 Expression of Dicer and EMT markers in a human mammary cancer progression cellular model. Expression of Dicer in the human breast tumour
progression cellular model:( A) western blot analysis of Dicer expression in the four human breast cell lines, namely HMEC, HMECþhTERT,
HMECþLTþhTERT, and HMLER (expressing H-rasV12) cells. The signal intensity of Dicer was normalised to that of actin. (B)The relative levels of Dicer
mRNA were measured by real-time RT–PCR, and each bar represents the mean±s.d. of the PCRs in triplicate ( ). Dicer protein levels were quantified
using Quantity One software (BioRad, Marnes-la-Coquette, France) and expressed as protein relative quantity. The ratios of Dicer/actin of three
independent studies were expressed as mean±s.d. ( ). Morphological characteristics and expression of epithelial and mesenchymal markers in the human
breast tumour progression cellular model:( C) Morphological characteristics of the HMECþhTERT, HMECþLTþhTERT, and HMLER cells in vitro as assessed
by phase-contrast microscopy. Images are shown at  40 magnification. (D) Western blot analysis of E-cadherin and vimentin expression in the four human
breast cell lines, HMEC, HMECþhTERT, HMECþLTþhTERT, and HMLER. Actin served as a loading control. E, epithelial phenotype; M, mesenchymal
phenotype.
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Figure 3 Expression of Dicer in metastasis progression cellular model and in bone metastatic cells. Expression of Dicer in the mouse metastasis progression
cellular model:( A) western blot analysis of Dicer expression in the five mouse mammary cell lines, namely 67NR, 168FARN, 4TO7, 66c14, and 4T1. The
signal intensity of Dicer was normalised to that of actin. (B) The relative levels of Dicer mRNA were measured by real-time RT–PCR, and each bar
represents the mean±s.d. of the PCRs in triplicate ( ). Dicer protein levels were quantified using Quantity One software (BioRad, Marnes-la-Coquette,
France) and expressed as protein relative quantity. The ratios of Dicer/actin of three independent studies were expressed as mean±s.d. ( ). E, epithelial
phenotype; M mesenchymal phenotype; E/M, mixed phenotype. Expression of Dicer in two bone metastatic derivatives of MDA-MB-231 cells:( C) western blot
analysis of Dicer expression in the three cell lines, namely MDA-MB-231, BO2, and SCP2. The signal intensity of Dicer was normalised to that of actin. (D)
The relative levels of Dicer mRNA were measured by real-time RT–PCR, and each bar represents the mean±s.d. of the PCRs in triplicate ( ). Dicer
protein levels were quantified using Quantity One software (BioRad, Marnes-la-Coquette, France) and expressed as protein relative quantity. The ratios of
Dicer/actin of three independent studies were expressed as mean±s.d. ( ).
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sinhibition of Dicer full-length protein, the decrease in mature
miRNA expression varied only between 40 and 60% 48h after the
second round of transfection (Supplementary Figure S2B). (Similar
results were obtained with the two different control siRNAs,
namely siCt1 and siCt2, and with the two different siRNAs
homologous to Dicer sequences, that is, si1Dcr and si2Dcr, data
not shown.)
We next analysed Dicer mRNA and protein expression levels in
21 human breast cancer cell lines and in HMECs. We investigated
the clinicopathological significance of Dicer mRNA expression in
the 21 cell lines and in HMECs. As we have found for the human
cancer progression cellular model, a very significant association
was observed between the mRNA levels of Dicer and cell
phenotype, with significantly lower levels in mesenchymal
phenotype cells (P¼0.0002, Table 1; Supplementary Figure S3).
Epithelial and mesenchymal phenotypes were determined using
phase-contrast microscopy and by examining E-cadherin and
vimentin expression by western blotting (data not shown).
Interestingly, Dicer mRNA expression was found to be tumour
stage-dependent, with increasing levels between immortalised cells
and cell lines established from ductal carcinoma in situ, and a
subsequent marked decrease in cell lines established from invasive
ductal carcinoma and in cell lines established from metastases
(P-value o0.0001, Table 1).
To determine whether mRNA levels (a, b, and c variants)
reflected full-length protein expression, 18 out of the 21 breast
cancer cell lines and HMECs cells were examined for Dicer protein
expression by western blotting. Semi-quantitative measures of
protein level showed 72% of concordance between RNA and
protein levels (Supplementary Figure S3). Overall, 74% of the cell
lines showed a significant association with epithelial–mesenchy-
mal phenotypes (Supplementary Figure S3).
By western blotting we detected two alternatively spliced
isoforms (113.2 and 93kDa) corresponding to the d and e variants,
respectively (Figure 1 and http://www.abcam.com/index.html?
pageconfig¼reviews&intAbreviewID¼4856&intAbID¼14601).
These variants were detectable in normal and immortalised cells,
they were highly expressed in some breast cancer cell lines of the
epithelial phenotype, and absent in the majority of the mesen-
chymal phenotype cell lines (data not shown).
Evaluation of the clinical and prognostic significance of
Dicer expression in breast cancer patients: association with
distant metastases
We further examined the potential clinical significance of Dicer
expression levels in breast cancer tissue samples obtained from
two independent populations of breast carcinomas. The clinical
characteristics of the two tumour populations are described in
Supplementary Table S1. There was a clear association between
Dicer mRNA expression and lymph node status; a significantly
lower mRNA Dicer expression was observed in cases with lymph
node metastases (N1: mean¼7.316 vs N0: mean¼12.240;
P¼0.0200, Supplementary Table S2). There was also a significant
association of mRNA levels with luminal A breast cancer subtype.
Dicer mRNA levels were lower in tumours that were not classified
as luminal A cancer subtype (luminal B, HER2þ, and basal like)
(luminal A: mean¼9. 487 vs non-luminal A: mean¼6.126;
P¼0.0481, Supplementary Table S2).
In a preliminary IHC analysis with eight normal mammary
gland tissues, Dicer protein was found to be expressed
uniformly in the cytoplasm of the luminal cells (Figure 4A). The
signal within the cytoplasm of luminal cells was weak (corres-
ponding to intensity 1). No positive immunoreactivity was
found either in basal or in stromal cells. In mammary tumour
cells, Dicer showed variable expression patterns. Some tumours
were negative for Dicer staining (data not shown), whereas
other tumour tissues showed a staining intensity comparable
with that found in normal tissues (intensity 1 and 460% of
stained cells) (Figure 4B). Nevertheless, other tumours showed
stronger cytoplasmic Dicer staining with a non-uniform pattern
in a reduced tumour cell population (intensity 2 and p60%
of stained cells) (Figure 4C). We have found a significant
inverse correlation between staining intensity and percentage
of stained cells (P¼0.013, Supplementary Table S3); there-
fore, either can be used as a staining score. The majority
(67%) of tumours in TMA analysis (58 out of 86) was of staining
intensity 1 and 62% (36 out of 58) of them showed more than
60% of stained cells compared with only 29% (5 out of 21) of
tumours showing staining intensity scored as 2 (Supplementary
Table S3).
We found a significant association between Dicer protein
expression and hormone receptor status. The intensity 1 and no
immunoreactivity were more frequently observed in ER- and
PR-positive tumours (ERþ 71.8% vs ER  46.7%, P¼0.008; PRþ
¼71.9% vs PR  54.6%, P¼0.019, Supplementary Table S3). The
population of tumours with negative staining (intensity 0) is
very small (7 out of 86); therefore, in statistical analysis we
grouped them with intensity 1 tumour population (Supplementary
Table S3).
Dicer protein expression was also correlated with cancer
subtype. Tumours of intensity 1 staining (identical to the intensity
staining found in normal luminal cells) were correlated with
luminal A cancer subtype (cancer subtype P¼0.023; luminal A
71.9% vs non-luminal A 52.6%, P¼0.0174, Supplementary
Table S3).
Finally, we examined whether Dicer mRNA and protein
expression could be useful in the prognosis of breast cancer
patients. Only mRNA expression showed association with patient
outcome (Figure 5). Protein levels were not predictive for patient’s
survival (data not shown). The probability of metastasis-free
survival was significantly lower for patients with levels of Dicer
mRNA o8 compared with those with levels 48 (Figure 5, HR:
3.36, P¼0.0032). Interestingly, when an adjustment was made
for each clinocopathological prognosis criteria, the HR values
remained generally similar and for the most part, significantly 41
(Table 2).
DISCUSSION
The aim of this study was to evaluate independently the clinical
relevance of RNA and the protein expression of Dicer in breast
carcinoma samples. Furthermore, we investigated whether Dicer
expression could vary during tumour and metastasis progression
Table 1 Quantitative RT–PCR analysis of Dicer expression in breast
cancer cell lines and correlation with clinicopathological characteristics
Biological and clinical Cases Measures
Dicer
characteristics n¼23 111 Mean CI P-value
Cell phenotype
Epithelial 11 55 4.056 (3.230–5.093) 0.0002
Mesenchymal 7 35 1.763 (1.363–2.282)
Tumour stage
Immortalized cell 3 15 2.198 (1.577–3.064) o0.0001
Intra-ductal carcinoma
(DCIS)
4 20 4.107 (3.445–4.895)
Invasive ductal
carcinoma (IDC)
12 60 1.524 (NA)
Metastases 1 5 1.369 (1.045–1.794)
CI¼confidence interval; RT–PCR¼reverse transcription PCR.
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susing human and mouse cellular models, as well as breast cancer
cell lines.
We have found that Dicer mRNA expression was variable in
breast carcinoma samples and that lower levels were more frequent
in patients with metastatic relapse, indicating that Dicer mRNA
levels are clinically relevant. Low mRNA levels were significantly
associated with cancer subtypes other than luminal A (luminal B,
HER2þ, and basal like) and with metastases to lymph nodes, both
of which are clinical parameters of aggressiveness. Interestingly,
we have shown that Dicer expression appeared downregulated in
two independent metastatic bone derivative clones of a breast
cancer cell line. Transcriptomic analyses that were carried out in
MDA-MB-231 parental and in BO2 clone have shown the same
decrease in Dicer expression (Bellahce `ne et al, 2007; Garcia et al,
2008) (R Bachelier and P Cle ´zardin, personal communication).
In Dicer-conditional knockout mice, the loss of Dicer resulted in
increased DNA damage (Mudhasani et al, 2008), and the timing
of locus replication during S-phase has been shown to be very
sensitive to the influence of Dicer hemi-depletion (Jørgensen et al,
2007). The study by Kumar et al, 2007 nicely showed that defective
miRNA processing machinery improves the transformation
capacities of cancer cells. Dicer expression has been previously
investigated in other tumour types and in breast cancers. Our
RT–PCR results are consistent with those of Blenkiron et al (2007)
who have found by microarray analysis low expression of Dicer in
luminal B, HER2þ, and basal-like tissues. A relationship between
high Dicer mRNA levels analysed by microarray and increased
disease-free survival was found in two different cohorts of patients
suffering from breast cancer (Merritt et al, 2008). Findings in other
tumour types showed decreased or increased Dicer expression
associated with aggressive cancers, evoking a tissue specificity of
Dicer deregulation expression in cancers. High Dicer expression
was found in prostate and in oesophageal carcinomas, whereas
downregulation was found in advanced lung adenocarcinoma
(Chiosea et al, 2006, 2007; Sugito et al, 2006). It is noteworthy that
the Dicer gene is located at the subtelomeric region 14q32.13,
which carries a cluster of imprinted genes critically affected by
various deletions, rearrangements, and epimutations that might
potentially influence the methylation status of this region during
tumour progression (Kagami et al, 2008). However, it has also
been shown that the Dicer gene was not methylated in lung cancers
(Karube et al, 2005), and that treatment of cells with a histone
deacetylase inhibitor does not change levels of Dicer mRNA, with
minimally altered Dicer message levels (Wiesen and Tomasi, 2009).
Abnormalities in the copy number of the Dicer gene were found
in breast and ovarian cancers, as well as in melanoma (Zhang
et al, 2006). Two studies in ovarian carcinomas appeared to be
contradictive on Dicer expression, showing in tumours of
epithelial type higher or lower Dicer expression both associated
Normal tissue
Ductal carcinoma
Ductal carcinoma
A
B
C
Figure 4 Immunohistochemical analysis of Dicer protein expression in normal and breast cancer tissues. (A) Low-intensity staining in the cytoplasm of
epithelial luminal normal breast cells. Non-specific staining of mast cells. (B) Low-intensity staining in the cytoplasm of infiltrating ductal carcinomatous cells.
(C) High-intensity staining in the cytoplasm of infiltrating ductal carcinomatous cells. Images are shown at magnification, 40 (panels A–C).
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Figure 5 Kaplan–Meier estimates of metastatic-free survival by Dicer’s
expression among the mRNA population. 48 cDNA relative quantity
(7 out of 43 progressions; 8-year event-free survival probability 88.3% (95%
CI: 77.3–99.3); p8 cDNA relative quantity (22 out of 45 progressions;
8-year event-free survival probability 49.1% (95% CI: 33.6–64.6); log-rank
test: P¼0.0032.
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swith poor prognosis (Flavin et al, 2008; Merritt et al, 2008). Merritt
et al. showed a significant association of Dicer mRNA levels with
survival, whereas Flavin et al. failed to show an association with
survival on the basis of protein expression. However, it is unclear
which Dicer isoforms were analysed in the two studies. Contrary to
other organisms, mammals have a single Dicer gene but its
expression is a highly regulated process with 11 alternatively
spliced variants and 3 full-length forms (http://www.ncbi.nlm.
nih.gov/ieb/research/acembly/). Characterisation of the 50UTR of
Dicer has defined three non-coding exon 1 variants as well as
several alternatively spliced non-coding 50exons, and the 3 full-
length forms show differences in 30UTR sequence (Irvin-Wilson
and Chaudhuri, 2005; Singh et al, 2005). Some spliced Dicer
mRNAs putatively encode transcribed proteins as we have shown
by western blotting that the two splice variants, d and e, were
highly expressed in some breast cancer cell lines, whereas totally
absent in others in addition to being detectable in normal and
immortalised breast cells. These variants showed 94% homology
with a long-form 50UTR variant expressed in breast cells, whereas
no homology was found with a short-form 50UTR variant also
expressed in breast cells (Irvin-Wilson and Chaudhuri, 2005). The
variants d and e were not only expressed in breast tissues but were
also detected in HeLa cells (data not shown). We may ask whether
the d and e isoforms could be functional as they both contain the
ribonuclease III domain, the dsRNA binding domain while only
the d isoform contains a PAZ domain. It has been shown
previously that Dicer functions both as a monomer and a dimer
(Carmell and Hannon, 2004). Given that the e variant contains two
ribonuclease domains, we expect it to function as a monomer and
the d variant with one ribonuclease domain to function as a dimer.
In our study, these variants were not targeted by siRNA in HeLa
cells, and the inactivation of full-length a, b, and c forms did not
lead to a complete elimination of mature miRNAs. One of the
miRNA species showed only 40% decreased expression; however,
we cannot exclude that some mature miRNAs may have long
turnover times and therefore the miRNA observed is residual
before the knock down of Dicer.
Regulation of Dicer expression seems largely post-transcrip-
tional as cellular Dicer mRNA measured by PCR is not well
correlated with protein expression (Wiesen and Tomasi, 2009).
The two previous studies on Dicer expression in breast cancers
failed to compare RNA and protein expression (Blenkiron et al,
2007; Merritt et al, 2008). In breast cancer cell lines, we have found
72% concordance between mRNA and protein levels. A high
correlation between protein and mRNA levels was found only for
breast cancer cell lines of the mesenchymal phenotype. Although
Dicer mRNA levels appeared to be predictive for metastasis-free
survival, protein expression was not informative for survival.
Furthermore, we obtained conflicting data between mRNA and
protein expression regarding association with clinical parameters.
Higher mRNA levels were correlated with luminal A cancer
subtype, whereas negative or weak immunoreactivty in the TMA
study were associated with this cancer subtype. It is noteworthy
that low immunoreactivity has the same level of staining observed
in normal breast tissues.
The Dicer protein is a part of the RISC loading, small RNA
processing complex, including its co-factor TRBP (TAR RNA
binding protein), PACT, and Ago2, which could affect its stability
depending on their respective expression in cancer cells (Chiosea
et al, 2006, 2007; Lee et al, 2006; Zhang et al, 2006; Blenkiron et al,
2007). Recent publications highlight the intricate complexity
of Dicer expression regulation showing that Dicer is a high
probability target of multiple miRNAs. Dicer is believed to be a
‘hub’ through a novel regulatory loop in which the mature miRNA
(primarily let-7) processed by Dicer affects Dicer expression at
both protein and mRNA levels (Johnson et al, 2007; Asirvatham
et al, 2008; Forman et al, 2008; Roush and Slack, 2008; Selbach
et al, 2008; Tokumaru et al, 2008). let-7 might confer varying
degrees of Dicer translational inhibition versus mRNA instability
depending on specific target sites. Recognition sites for miRNAs
have been reported to be mainly located at the 30UTR of
transcripts. The Dicer RNA variants a and b contain a very long
30UTR, whereas c, d, and e variants contain very short 30UTR
(Figure 1). Multiple let-7-binding sites were found in Dicer 30UTR
(Forman et al, 2008). Recently, let-7 target sites were also found in
the Dicer coding region, and it was suggested that sites in the
coding region and in 30UTR may differ in mechanism (Forman
et al, 2008; Selbach et al, 2008). Multiplicity of miRNA-binding
sites in the same 30UTR exerts a stronger effect on protein
production than on mRNA levels (Selbach et al, 2008). It is
noteworthy that binding of miRNA in the 30UTR has only mild
effects on translation. In the coding region, a greater number of
nucleotides which bind to miRNA, suggest that these sites may
activate mRNA degradation similar to that in Arabidopsis (Xie
et al, 2003). let-7 miRNAs are largely expressed in many tissues,
including the mammary gland (Landgraf et al, 2007). Human let-7
Table 2 Metastasis free survival—comparison of the stratified hazard ratios
Metastatic progression
TMA population mRNA population
Subgroups Metaprog/N HR (95% CI) (2 vs 0/1) Metaprog/N HR (95% CI) (o¼8v s48)
Overall 13/79 1.25 (0.38–4.05) 29/87 3.36 (1.43–7.92)
Adjusted effect on age 13/79 1.38 (0.42–4.51)
a 29/85 3.60 (1.53–8.47)
Adjusted effect on menopause 13/79 1.19 (0.37–3.88) 29/86 3.24 (1.37–7.67)
Adjusted effect on pT 13/79 1.77 (0.53–5.93) 29/86 3.23 (1.36–7.65)
Adjusted effect on histological type 13/79 1.05 (0.32–3.42)
a 29/86 2.99 (1.27–7.05)
Adjusted effect on SBR 13/79 0.96 (0.29–3.17) 28/81 3.14 (1.32–7.45)
Adjusted effect on N 13/79 1.19 (0.36–3.93) 29/87 2.77 (1.17–6.52)
Adjusted effect on ER (%) 13/79 0.84 (0.23–3.03) 28/84 3.14 (1.32–7.47)
Adjusted effect on PR (%) 13/79 0.90 (0.26–3.14) 29/86 3.23 (1.37–7.62)
Adjusted effect on HER2 13/79 1.34 (0.40–4.48) 21/64 2.26 (0.85–6.00)
Adjusted effect on luminal A 12/77 1.07 (0.30–3.83) 21/63 2.64 (0.99–7.00)
Adjusted effect on cancer subtype 12/77 0.76 (0.18–3.18) 21/63 2.59 (0.97–6.89)
CI¼confidence interval; ER¼estrogen receptor; HR¼hazard ratio; HER2¼human epidermal growth factor receptor 2; N¼lymph node status; PR¼progesterone receptor;
SBR¼Scarff-Bloom-Richardson; TMA¼tissue microarray. If HR41, the patient has a higher risk to have a metastatic reccurrence at time t compared with the reference item.
If HR o1, patient has a lower risk to have a metastatic reccurrence at time t compared with the reference item.
aAdjusting parameter statistically significant in the model.
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sgenes map to regions altered or deleted in human tumours, and
the majority of let-7 family members is considered as tumour
suppressor miRNAs, with decreased expression in different
tumour types, such as serous ovarian carcinomas and lung
tumours (Takamizawa et al, 2004; Johnson et al, 2007; Nam
et al, 2008). We can hypothesise that in normal and immortalised
mammary cells and in breast tumours with good prognosis
(luminal A cancer subtype) let-7 miRNAs repress the translation of
Dicer variants with long 30UTR, whereas they induce the down-
expression of the short 30UTR variants. In some cancer cells, let-7
downregulation may render the long 30UTR variants accessible to
other miRNAs or RNA binding proteins that affect mRNA stability
and thus may lead to a switch in the variant’s downregulation
(Selbach et al, 2008). In other cancer cells, expression of some
miRNAs may lead to the degradation of all variants. In HMLER
cells and in mesenchymal phenotype cancer cell lines, we have
found both decreased expression of mRNA and of the three
protein forms (full length, d and e spliced forms). We cannot rule
out that alterations in the Dicer gene or in Dicer gene expression
may exist in these cells. Breast tumours of the mesenchymal
phenotype are metaplastic carcinomas that are rare in clinical
practice. Recently, it has been shown that metaplastic carcinomas
represent a subtype of basal-like cancers (Weigelt et al, 2008).
However, the mesenchymal phenotype may not be a prerequisite
for tumour cells to become metastases. The cells expressing
hTERT, LT, and H-rasV12 (HMLER) form colonies in soft agar and
tumours in nude mice (Elenbaas et al, 2001). No signs of metastatic
spread are observed in tumour-bearing mice. The mesenchymal
phenotype is not correlated with the capacity of the cells to
metastasise in the 67 NR mouse model (Lou et al, 2008). Lou et al
recently showed that 67NR and 66c14 sub-lines exhibit morpho-
logical characteristics of the mesenchymal phenotype. 168FARN
are a mixed population with predominance of the mesenchymal
population. Finally, the metastatic sub-lines, 4T07 and 4T1 exhibit
epithelial characteristics. Cells of the mesenchymal phenotype
express less Dicer protein than those of the epithelial phenotype,
but more specifically there was an inverse correlation between
Dicer and vimentin protein levels in the sub-lines. 4T1 cells (E)
showed high levels of E-cadherin and weak expression of vimentin,
66c14 (M) expressed no E-cadherin but vimentin with the same
levels found in 4T1 cells, and 67NR (M) did not express E-cadherin
but vimentin at high levels (Lou et al, 2008).
In conclusion, Dicer mRNA expression is significantly corre-
lated with the occurrence of distant metastases, even after adjust-
ing for other prognostic parameters. We found that Dicer mRNA
expression had an independent prognostic value on metastatic
disease in breast cancers. Our findings suggest that the down-
regulation of Dicer expression may be related to aggressiveness
and metastatic spread of tumours. Thus, we propose that Dicer
mRNA be considered as a novel predictive biomarker in breast
cancer metastatic disease. Further definition of the variant(s)
responsible for the association between RNA expression levels and
metastatis-free survival (i.e., between variants a, b, and c) could
also increase the power of the marker in other types of cancer.
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